| Autor: |
Patel, KJ, Best, JR, Yang, D, Chambers, C, Lee, PE, Henri-Bhargava, A, Funnell, CR, Foti, DJ, Feldman, HH, Pettersen, JA, Nygaard, HB, Hsiung, GR, DeMarco, ML |
| Zdroj: |
The Canadian Journal of Neurological Sciences; June 2023, Vol. 50 Issue: Supplement 2 pS58-S59, 2p |
| Abstrakt: |
Background: Within the IMPACT-AD BC study, we sought to address the gap in knowledge around how the use of Alzheimer’s disease (AD) CSF biomarker testing impacts clinical management. Methods: IMPACT-AD BC (NCT05002699, impactAD.org) is an observational, longitudinal study examining the role of AD CSF biomarker testing (i.e., amyloid-beta and tau proteoforms) in medical and personal decision-making, and health economics. For medical decision-making, physicians completed surveys on patient management plans before and after receiving the biomarker findings. Overall change in management was assessed as a composite measure of changes in the use of: (i) AD symptomatic medications, (ii) other dementia-relevant medications, (iii) diagnostic procedures, and (iv) referrals or counselling. Results: Of the 142 participants, 66% were determined to have CSF biomarker profiles on the AD continuum. Overall change in management was observed in 89% of patients, with the greatest changes by category being: diagnostic procedures > referrals and counselling > AD symptomatic medications > other dementia-relevant medications. Conclusions: The use of AD CSF biomarker testing increases diagnostic confidence and aids in medical decision-making. Notably, the addition of biomarker testing leads to a reduction in the use of other diagnostic procedures, helps optimize pharmacotherapy and results in increased physician-patient/family member counselling. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
